Mixing & Administration Guide

How this tool works · sources read September 30, 2026 · Grey Peptides Editorial Board

What this guide rests on

Approved peptide drugs come with instructions tested for that product: which liquid to use, how to mix it, where to inject it and how long it keeps. Research peptides come with none. This guide takes its steps from the nearest thing to a standard that exists: the labels and instructions of approved injectable drugs, injection-technique guidelines written for insulin, which is the most studied under-the-skin injection, and published data on storage and contamination. Where a step has no source, the guide no longer states it.

Choosing the liquid

Two liquids are used, and they are not interchangeable. Bacteriostatic water for injection is sterile water with 0.9% benzyl alcohol added as a preservative, sold in multiple-dose vials from which repeated withdrawals can be made; its label warns that it must not be used in newborns, because benzyl alcohol is toxic to them.¹ Sterile water for injection has no preservative. It is what EGRIFTA SV supplies with its 2 mg vial, and that label says to inject the dose immediately after mixing and throw the rest away.²

The preservative's job is to limit the growth of bacteria introduced each time a needle goes through the stopper. It does nothing to slow the chemical breakdown of the peptide. That is why an opened multiple-dose vial has a beyond-use date: date it when first punctured and discard it within 28 days, unless the manufacturer specifies otherwise.³ The date is a sterility limit, not a promise that any particular peptide is still intact on day 27.

Mixing without damaging the drug

Labels for freeze-dried peptide and protein drugs share a pattern: add the liquid gently, mix by rolling or swirling, and never shake. EGRIFTA SV's instruction is to roll the vial gently between the hands for 30 seconds, not to shake it, and to use the solution only if it is clear, colourless and free of particles.² A cloudy solution, visible particles or a colour the product should not have are reasons not to inject it. GHK-Cu is the expected exception to "colourless": the copper complex is blue.

Injection technique

The most detailed injection-technique guidance comes from diabetes care. The international FITTER recommendations, written by 183 experts from 54 countries, advise the shortest needles as the first choice for everyone: 4-mm pen needles and 6-mm syringe needles, which are as effective and less painful than longer ones. They advise against injecting into muscle, which speeds absorption, and they identify lipohypertrophy, a lumpy thickening of fat at overused sites, as a frequent complication that distorts absorption and is prevented by rotating sites.⁴

For the drugs whose labels have tested it, the site makes little difference to exposure: semaglutide gives similar exposure in the abdomen, thigh and upper arm.⁵ The instructions for the tirzepatide pens place abdominal injections at least 2 inches from the belly button and ask users to change the site each week.⁶ Use a new needle for every injection and never share a vial, a pen or a needle, even with a new needle attached.

Short needles work because skin is thinner and more uniform than most people expect. In adults with diabetes aged 18 to 85, skin averaged 2.2 mm thick on the arm, 1.9 mm on the thigh, 2.2 mm on the abdomen and 2.4 mm on the buttocks, and body size, sex and ethnicity changed it only slightly; the fat beneath was thicker and far more variable, from 10.4 mm on the thigh to 15.4 mm on the buttocks on average, with women carrying about 5 mm more.⁷ A 4-mm needle therefore reaches the fat in almost everyone, while longer needles are more likely to reach muscle.

The site can still change absorption for some drugs. In 21 healthy men given fast-acting insulin aspart, the time to appear in the blood and to peak was similar in the abdomen, upper arm and thigh, but exposure in the first hours was about 25% lower from the thigh.⁸ Where a label says the site does not matter, as it does for semaglutide, that finding is specific to the drug tested.

Rotation is what prevents lipohypertrophy. A diabetes nurse examining 430 insulin users in Spain found it in 64.4% of them; only 5% of those who rotated correctly had it, and 98% of those who had it rotated incorrectly or not at all. People with lipohypertrophy had unexplained low blood sugar far more often (39.1% against 5.9%) and used more insulin (56 units a day against 41), and the risk rose significantly once a needle was reused more than five times.⁹ Never inject into a lump, and rotate systematically within each site.

Storage

A refrigerator set to the right temperature is not necessarily at that temperature. When 338 people placed temperature sensors next to their insulin, every one of the 230 sensors kept in a home refrigerator recorded readings outside the recommended range; on average the insulin was out of range 11.3% of the time, about 2 hours 43 minutes a day, and 17% of all sensors recorded temperatures below freezing.¹⁰ CDC's vaccine storage guidance tells clinics not to keep vaccines in the refrigerator door, where temperature and airflow are least stable, and to keep them away from vents and cooling elements.¹¹ The same logic applies to a peptide vial: middle shelf, main compartment, ideally with a thermometer.

Approved products state their limits exactly. An Ozempic pen, for example, must be refrigerated before first use, must not be frozen or used if it has been frozen, and can be kept for 56 days after first use at room temperature or in the refrigerator.⁵ Research peptides have no such label, and for most of them stability has not been published, so the storage table on this page gives rules rather than shelf lives.

Contamination

Every puncture of a stopper is a chance for bacteria to get in. When a hospital cultured 205 opened single- and multiple-dose vials, 11 (5.4%) were contaminated, most of them insulin vials, and the authors traced the problem to lapses in aseptic technique.¹² That is the reason for the steps that feel fussy: an alcohol swab on the stopper every time, allowed to dry; a fresh needle for each withdrawal; and a vial that belongs to one person only.

Disposing of needles

FDA's guidance is to put used needles and syringes straight into a sharps disposal container, or, if none is available, a heavy-duty plastic household container such as a laundry-detergent bottle, and never to put loose needles in household or public trash or recycling, or flush them.¹³ Local rules on disposing of the full container vary.

Is there a peptide compatibility chart? Mixing two in one syringe

The labels are consistent about it. Ozempic, Mounjaro, Trulicity and Byetta each tell patients who also use insulin to give separate injections and never mix the products; Victoza says to give separate injections; and Zepbound's instructions say not to mix it with any other medicine.^{14,15,16,17,18,19} Where the combination is wanted, manufacturers make it one product that was tested and approved as such: Soliqua 100/33 combines insulin glargine with lixisenatide, and Xultophy 100/3.6 combines insulin degludec with liraglutide.^20,21

Drawing two drugs into one syringe is also, in pharmacy terms, compounding. USP's sterile compounding chapter defines it as combining, admixing, diluting, pooling, reconstituting, repackaging or otherwise altering a drug to create a sterile preparation; preparing a product exactly as its label directs is outside the chapter, and none of the labels above directs mixing.²² Its exemption for immediate use in health-care settings still requires administration to begin within 4 hours and allows no more than three sterile products.²³

For research peptides there is nothing to put in a compatibility chart. We searched PubMed on September 30, 2026 for compatibility or stability studies of research-peptide mixtures in a syringe, including BPC-157, TB-500, ipamorelin and CJC-1295, and found none. A chart for them would be a guess presented as data. Separate injections, at separate sites, avoid the question.

Sources

1. Hospira, Inc. Bacteriostatic Water for Injection, USP, prescribing information: 0.9% (9 mg/mL) benzyl alcohol as a bacteriostatic preservative; multiple-dose container; not for use in neonates. DailyMed version of July 8, 2026, read September 30, 2026.
2. Theratechnologies Inc. EGRIFTA SV (tesamorelin) for injection, US prescribing information: reconstitute with 0.5 mL of the supplied Sterile Water for Injection; mix by rolling the vial gently for 30 seconds, do not shake; use only if clear, colorless and without particulate matter; administer immediately and discard unused solution. DailyMed version of July 31, 2026, read September 30, 2026.
3. The Joint Commission. Multi-dose vials: managing multi-dose vials of injectable medication (standards FAQ): an opened or accessed multiple-dose vial is dated and discarded within 28 days unless the manufacturer specifies a different date. Read September 30, 2026. Joint Commission
4. Frid, A. H. et al. (2016). New Insulin Delivery Recommendations. Mayo Clinic Proceedings, 91(9), 1231-1255. PMID: 27594187 · doi:10.1016/j.mayocp.2016.06.010
5. Novo Nordisk. OZEMPIC (semaglutide) injection, US prescribing information: similar exposure after injection in the abdomen, thigh or upper arm; refrigerate before first use, do not freeze and do not use if frozen; after first use the pen can be stored for 56 days at 15-30 °C or 2-8 °C. DailyMed version of June 10, 2026, read September 30, 2026.
6. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, Instructions for Use: inject in the thigh or stomach at least 2 inches from the belly button; change (rotate) the injection site each week. DailyMed version of September 2, 2026, read September 30, 2026.
7. Gibney, M. A. et al. (2010). Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Current Medical Research and Opinion, 26(6), 1519-1530. PMID: 20429833 · doi:10.1185/03007995.2010.481203
8. Hövelmann, U. et al. (2017). Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. Clinical Drug Investigation, 37(5), 503-509. PMID: 28185141
9. Blanco, M. et al. (2013). Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes and Metabolism, 39(5), 445-453. PMID: 23886784 · doi:10.1016/j.diabet.2013.05.006
10. Braune, K. et al. (2019). Storage Conditions of Insulin in Domestic Refrigerators and When Carried by Patients: Often Outside Recommended Temperature Range. Diabetes Technology and Therapeutics, 21(5), 238-244. PMID: 31009254 · doi:10.1089/dia.2019.0046
11. Centers for Disease Control and Prevention. Vaccine Storage and Handling Toolkit: do not store vaccines in the refrigerator door or near vents; store away from walls and cooling elements. Wording confirmed September 30, 2026. CDC
12. Baniasadi, S. et al. (2013). Microbial contamination of single- and multiple-dose vials after opening in a pulmonary teaching hospital. Brazilian Journal of Infectious Diseases, 17(1), 69-73. PMID: 23294643 · doi:10.1016/j.bjid.2012.09.005
13. US Food and Drug Administration. Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel. Content current as of November 19, 2021; read September 30, 2026. FDA
14. Novo Nordisk. OZEMPIC (semaglutide) injection, US prescribing information, section 2: when using OZEMPIC with insulin, administer as separate injections and never mix the products. DailyMed version of June 10, 2026, read September 30, 2026.
15. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, US prescribing information, section 2: when using MOUNJARO with insulin, administer as separate injections and never mix. DailyMed version of September 2, 2026, read September 30, 2026.
16. Eli Lilly and Company. TRULICITY (dulaglutide) injection, US prescribing information, section 2: when using TRULICITY with insulin, administer as separate injections and never mix. DailyMed, read September 30, 2026.
17. AstraZeneca. BYETTA (exenatide) injection, US prescribing information, section 2: when using BYETTA with insulin, administer as separate injections and never mix. DailyMed, read September 30, 2026.
18. Novo Nordisk. VICTOZA (liraglutide) injection, US prescribing information, section 2: when using VICTOZA with insulin, administer as separate injections. DailyMed, read September 30, 2026.
19. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, Instructions for Use: do not mix ZEPBOUND with any other medicine. DailyMed version of September 2, 2026, read September 30, 2026.
20. Sanofi-Aventis U.S. SOLIQUA 100/33 (insulin glargine and lixisenatide) injection, US prescribing information: a combination of insulin glargine and lixisenatide in one product. DailyMed version of March 20, 2026, read September 30, 2026.
21. Novo Nordisk. XULTOPHY 100/3.6 (insulin degludec and liraglutide) injection, US prescribing information: a combination of insulin degludec and liraglutide in one product. DailyMed version of November 17, 2025, read September 30, 2026.
22. United States Pharmacopeia (2023). General Chapter <797> Pharmaceutical Compounding - Sterile Preparations, section 1 (scope and definition of sterile compounding). USP-NF. Read September 30, 2026. USP
23. United States Pharmacopeia. <797> FAQs, General Introduction and Scope (November 1, 2022): immediate-use CSPs must begin administration within 4 hours of the start of preparation and involve no more than 3 different sterile products. Read September 30, 2026.

This explainer describes how the tool works and what its numbers rest on. It is not medical advice and does not recommend any dose or product.